CAR-T Therapy for Multiple Myeloma at Sheba Medical Center
What's included in this package
Medical Procedures
- CAR T-cell therapy
- Blood tests
- Biochemistry blood test
- Biopsy
- CT Scan
- Consultation with a doctor
- Consultation with an oncologist
- Consultation with a hematologist
- Consultation with an immunologist
- Consultation with a pediatric hematologist
- Complete blood count with cancer markers and a proteinogram
- CT angiography
- Electrocardiogram (ECG)
- Follow-up examination
- PET/CT
- Ultrasound biomicroscopy (UBM)
- Ultrasound
- Сonsultation with an oncohematologist
- 24-hr nurse services
- 3 meals per day by nutritionist
Duration
- 21 days in the hospital
Accommodation
Hospitalization
Transport
Transfer airport-clinic-airport
Additional information
CAR-T Therapy for Multiple Myeloma at Sheba Medical Center
For patients diagnosed with Multiple Myeloma, especially those with relapsed or treatment-resistant disease, access to advanced therapies can significantly change outcomes.
Sheba Medical Center, one of the world’s leading hospitals, offers state-of-the-art CAR-T cell therapy, providing new hope when standard treatments are no longer effective.
Sheba combines innovative immunotherapy, extensive clinical experience, and rapid access to treatment to deliver highly personalized care for complex myeloma cases.
A Faster Path to Advanced Treatment
At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality what is a key advantage for patients requiring timely intervention.
• Apheresis – collection of the patient’s T-cells
• Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center
• Infusion – reinfusion of modified cells designed to recognize and destroy myeloma cells
By avoiding external laboratories, treatment can begin in approximately 10 days, significantly reducing waiting time compared to many international centers.
CAR-T therapy acts as a “living therapy,” continuing to function within the body and offering the potential for deep and durable remission.
All patients are treated under the leadership of Prof. Arnon Nagler, a globally recognized expert in hemato-oncology.
A Powerful Option for Advanced Myeloma
Multiple Myeloma often requires multiple lines of therapy over time. At Sheba, hematologists, oncologists, and immunotherapy specialists work together to develop a personalized treatment strategy, especially for patients who have exhausted conventional options.
CAR-T therapy has shown promising and durable responses in advanced myeloma, offering a new therapeutic pathway where alternatives may be limited.
Why Patients Choose Sheba
• Rapid access to CAR-T therapy – treatment initiation in ~10 days
• Extensive experience – one of the leading CAR-T programs in the region
• Dedicated CAR-T units – with 24/7 expert monitoring
• Multidisciplinary expertise – integrated care across specialties
• Full international support – medical review, travel coordination, and patient assistance
Comprehensive, Personalized Care
Each patient undergoes a complete diagnostic evaluation, including advanced imaging, bone marrow biopsy, genetic and molecular testing, and full medical assessment, ensuring a precise, individualized treatment plan.
Services are provided in English, Russian, and Arabic, ensuring a smooth and supportive experience for international patients.
A Leading Center for Advanced Myeloma Treatment
By combining innovative CAR-T technology, in-house cell production, and world-class expertise, Sheba delivers one of the most advanced and accessible CAR-T programs for Multiple Myeloma worldwide offering patients a real opportunity for long-term disease control and improved quality of life.
24/7 Bookimed assistance
- Personal medical coordinator
- Medical travel arrangements — booking of air tickets and hotel rooms at special partner prices
- Patient advocacy during medical travel
Program price
What's NOT included in this package
Doctor
Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.
He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.
He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.
How are we doing?
About the clinic
Sheba Medical Center, Israel’s leading hospital, is consistently ranked among the world’s top institutions. Treating over 2 million patients annually, Sheba combines world-class expertise with compassionate, personalized care. Its “City of Health” campus integrates six specialized hospitals, offering advanced treatments in oncology, neurology, cardiology, orthopedics, and more. Sheba is a global leader in CAR-T and TIL immunotherapies, precision medicine, and minimally invasive surgery, making it a trusted destination for international patients seeking cutting-edge healthcare.
Payment & Rewards
You don’t pay for our services
You make your payment directly at the clinic or to their official bank account.
Some clinics may require a deposit as a part of their policy.
Spread out your payments with installment options.
Earn rewards for referring friends to Bookimed.